A randomized trial of low-dose aspirin in the prevention of clinical type 2 diabetes in women

Aruna D Pradhan, Nancy R Cook, Joann E Manson, Paul M Ridker, Julie E Buring, Aruna D Pradhan, Nancy R Cook, Joann E Manson, Paul M Ridker, Julie E Buring

Abstract

Objective: Subclinical inflammation is linked with the development of type 2 diabetes, and epidemiologic data suggest that this association may be stronger in women. Although small clinical studies have shown a prominent hypoglycemic effect of short-term high-dose aspirin, no randomized trials have directly evaluated the efficacy of aspirin in diabetes prevention at doses acceptable for use in routine clinical practice. We evaluated whether chronic low-dose aspirin prevents the development of clinical diabetes among initially healthy American women.

Research design and methods: Subjects were enrolled in the Women's Health Study, a 10-year randomized double-blind, placebo-controlled trial of aspirin and vitamin E for primary prevention of cardiovascular disease and cancer. Between 1992 and 1995, 38,716 women aged > or =45 years and free of clinical diabetes were randomly assigned to either low-dose aspirin or placebo (median follow-up 10.2 years). Documented clinical type 2 diabetes was prospectively evaluated throughout the trial.

Results: Among women randomly assigned to receive aspirin (n = 19,326) or placebo (n = 19,390), there was no statistically significant difference in the incidence of type 2 diabetes. There were 849 cases of diabetes in the aspirin group and 847 in the placebo group (rate ratio 1.01 [95% CI 0.91-1.11]). Stratification by diabetes risk factors including age, BMI, family history of diabetes, physical activity, A1C, and high-sensitivity C-reactive protein did not support a modulating effect of these variables. Analyses accounting for treatment duration and adherence similarly found no beneficial effects.

Conclusions: These data suggest that long-term low-dose aspirin does not prevent the development of clinical type 2 diabetes in initially healthy women.

Trial registration: ClinicalTrials.gov NCT00000479.

Figures

Figure 1
Figure 1
Cumulative incidence of type 2 diabetes in the aspirin and placebo groups.

References

    1. Ebstein W: Zur therapie des diabetes mellitus, insbesondere uber die anwendeng der salicylauren natron bei demselben. Berlin Klin Wochenschr 13:337–340, 1876
    1. Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance. J Clin Invest 116:1793–1801, 2006
    1. Thorand B, Baumert J, Kolb H, Meisinger C, Chambless L, Koenig W, Herder C: Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984–2002. Diabetes Care 30:854–860, 2007
    1. Fleischman A, Shoelson SE, Bernier R, Goldfine AB: Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 31:289–294, 2008
    1. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293:1673–1677, 2001
    1. Gao Z, Zuberi A, Quon MJ, Dong Z, Ye J: Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. J Biol Chem 278:24944–24950, 2003
    1. Reid J, Lightbody TD: The insulin equivalence of salicylate. Br Med J 1:897–900, 1959
    1. Micossi P, Pontiroli AE, Baron SH, Tamayo RC, Lengel F, Bevilacqua M, Raggi U, Norbiato G, Foa PP: Aspirin stimulates insulin and glucagon secretion and increases glucose tolerance in normal and diabetic subjects. Diabetes 27:1196–1204, 1978
    1. Prince RL, Larkins RG, Alford FP: The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects. Metabolism 30:293–298, 1981
    1. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI: Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109:1321–1326, 2002
    1. Chiang N, Bermudez EA, Ridker PM, Hurwitz S, Serhan CN: Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A 101:15178–15183, 2004
    1. Santilli F, Davi G, Consoli A, Cipollone F, Mezzetti A, Falco A, Taraborelli T, Devangelio E, Ciabattoni G, Basili S, Patrono C: Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 47:391–397, 2006
    1. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352:1293–1304, 2005
    1. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE: Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294:47–55, 2005
    1. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE: Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 294:56–65, 2005
    1. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE: Baseline characteristics of participants in the Women's Health Study. J Womens Health Gend Based Med 9:19–27, 2000
    1. Liu S, Lee IM, Song Y, Van Denburgh M, Cook NR, Manson JE, Buring JE: Vitamin E and risk of type 2 diabetes in the Women's Health Study randomized controlled trial. Diabetes 55:2856–2862, 2006
    1. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197, 1997
    1. Ding EL, Song Y, Manson JE, Pradhan AD, Buring JE, Liu S: Accuracy of administrative coding for type 2 diabetes in children, adolescents, and young adults. Diabetes Care 30:e98, 2007; author reply e99
    1. Ealovega MW, Tabaei BP, Brandle M, Burke R, Herman WH: Opportunistic screening for diabetes in routine clinical practice. Diabetes Care 27:9–12, 2004
    1. Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH: β-Carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 91:2102–2106, 1999
    1. Giugliano D, Torella R, Siniscalchi N, Improta L, D'Onofrio F: The effect of acetylsalicylic acid on insulin response to glucose and arginine in normal man. Diabetologia 14:359–362, 1978
    1. Newman WP, Brodows RG: Aspirin causes tissue insensitivity to insulin in normal man. J Clin Endocrinol Metab 57:1102–1106, 1983
    1. Bratusch-Marrain PR, Vierhapper H, Komjati M, Waldhausl WK: Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic man. Diabetologia 28:671–676, 1985
    1. Centers for Disease Control and Prevention: National Diabetes Surveillance System: incidence of diabetes [article online], 2007. Available from . Accessed 21 May 2008

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다